are chemically similar to digoxin, and are distributed throughout the plant, either fresh or dried (LANGFORD & BOOR, 1996; SOTO-BLANCO et al., 2006).
Scheiner-Bobis, "Endogenous and exogenous cardiac glycosides
: their roles in hypertension, salt metabolism, and cell growth," American Journal of Physiology.
Heart Failure, Atrial Arrythmias, and Cardiac Glycosides
' Effects on the Diseased Heart
(12) In summary, cardiotoxic plant poisonings may cause serious dysrhythmias and death and will require intensive care management with combinations of gastrointestinal decontamination with oral-activated charcoal, intravenous vasopressor support, anti-arrhythmics, temporary pacemaker or temporary cardiopulmonary bypass, and few specific antidotes, with the exception of digoxin-specific Fab in cases of confirmed cardiac glycoside
This finding is particularly exciting because specific up-regulation of a proapoptotic factor, FasL, by a cardiac glycoside
has not previously been described.
1962 Cardiac Glycosides
, VI Moraceae: The Genus Antiaris Lesch.
Currently, heart failure patients are treated with diuretics such as furosemide to reduce water volume; cardiac glycosides
such as digoxin, which produce a positive inotropic effect in cardiac muscles to improve cardiac output; inhibitors of the renin-angiotensin-aldosterone system such as angiotensin converting enzyme inhibitors; and medications that block [beta]-adrenergic receptors to the deleterious effects of neurohormones.
Oleandrin: a cardiac glycosides
with potent cytotoxicity.
The kernel of its fruit contains various toxic principles; the important one is Cerberin, a cardiac glycoside
almost similar to digitalis in its toxicity.
(5,6) Digoxin is a cardiac glycoside
that inhibits Na/K-ATPase, thus causing a transient increase in intracellular sodium and then an increase in calcium by way of the sodium-calcium exchange mechanism.
Figure 1 shows the content of cardiac glycoside
, calculated as % digitoxin, in the various Thevetia seed meal samples and the results showed a marked reduction in glycoside content irrespective of detoxification method employed.
(2) describe studies that support the possibility of de novo biosynthesis, in the adrenal, of a material whose overall physicochemical, immunocrossreactive, and chromatographic characteristics are indistinguishable from those of the cardiac glycoside
(CG) digoxin and its dihydro analog (in which the lactone ring is fully saturated).